NO20060114L - Naftylenderivater som cytokrom P450-inhibitorer - Google Patents

Naftylenderivater som cytokrom P450-inhibitorer

Info

Publication number
NO20060114L
NO20060114L NO20060114A NO20060114A NO20060114L NO 20060114 L NO20060114 L NO 20060114L NO 20060114 A NO20060114 A NO 20060114A NO 20060114 A NO20060114 A NO 20060114A NO 20060114 L NO20060114 L NO 20060114L
Authority
NO
Norway
Prior art keywords
cytochrome
inhibitors
treatment
naphthylene
derivatives
Prior art date
Application number
NO20060114A
Other languages
English (en)
Inventor
Vanessa Smith
Anthony Nigro
Mark Mulvihill
Cara Cesario
Patrica Anne Beck
Arlindo L Castelhano
Original Assignee
Osi Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osi Pharm Inc filed Critical Osi Pharm Inc
Publication of NO20060114L publication Critical patent/NO20060114L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Forbindelser med formel og farmasøytisk akseptable salter derav, hvor ni, n2, n3, n4, G\ Q\ Z, R\ R', R', R'^ R'', R'^ og R'" er definert her, hemmer cytokrom P450RAI-enzymet og er anvendehge for behandling og/eller forebygging av forskjellige sykdommer og hdelser som responderer på behandling med retinoider og med naturlig forekommende retinsyre.
NO20060114A 2003-07-10 2006-01-06 Naftylenderivater som cytokrom P450-inhibitorer NO20060114L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48638203P 2003-07-10 2003-07-10
PCT/US2004/022282 WO2005007631A1 (en) 2003-07-10 2004-07-12 Naphthylene derivatives as cytochrome p450 inhibitors

Publications (1)

Publication Number Publication Date
NO20060114L true NO20060114L (no) 2006-02-09

Family

ID=34079229

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060114A NO20060114L (no) 2003-07-10 2006-01-06 Naftylenderivater som cytokrom P450-inhibitorer

Country Status (15)

Country Link
EP (1) EP1654236A1 (no)
JP (1) JP4832295B2 (no)
KR (1) KR20060052799A (no)
CN (1) CN1819996B (no)
AU (1) AU2004257257B2 (no)
BR (1) BRPI0412424A (no)
CA (1) CA2532078A1 (no)
IL (1) IL172812A0 (no)
IS (1) IS8223A (no)
MX (1) MXPA06000401A (no)
NO (1) NO20060114L (no)
RU (1) RU2363696C2 (no)
SG (1) SG144941A1 (no)
UA (1) UA87822C2 (no)
WO (1) WO2005007631A1 (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005058301A1 (en) * 2003-12-17 2005-06-30 Allergan, Inc. Methods for treating retinoid responsive disorders using selective inhibitors of cyp26a and cyp26b
US7662844B2 (en) 2004-07-12 2010-02-16 Osi Pharmaceuticals, Inc. Naphthylene derivatives as cytochrome P450 inhibitors
US10414760B2 (en) 2016-11-29 2019-09-17 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
EP2576544A4 (en) 2010-06-01 2013-09-11 Angion Biomedica Corp INHIBITORS OF CYTOCHROMES P450 AND USES THEREOF
EP3483147A1 (en) * 2010-11-13 2019-05-15 Innocrin Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CA2820718A1 (en) * 2010-12-13 2012-06-21 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CN102586187A (zh) * 2012-02-23 2012-07-18 深圳市中美康士生物科技有限公司 一种中性粒细胞体外保存方法及培养基
WO2014015137A2 (en) * 2012-07-18 2014-01-23 Angion Biomedica Corp. Compositions and methods for treating dysproliferative diseases
AU2015301891B2 (en) 2014-08-11 2019-12-05 Angion Biomedica Corporation Cytochrome P450 inhibitors and uses thereof
CN104523967B (zh) * 2014-12-12 2017-08-01 扬子江药业集团北京海燕药业有限公司 一种柏艾胶囊作为cyp酶抑制剂的应用
CN107531631B (zh) 2014-12-31 2021-09-03 安吉昂生物医药公司 用于治疗疾病的方法和药剂
GB201602572D0 (en) * 2016-02-12 2016-03-30 Eriksson Leif And Strid Ake And Sirsjö Allan New compound and uses
WO2018065288A1 (de) 2016-10-07 2018-04-12 Bayer Cropscience Aktiengesellschaft 2-[2-phenyl-1-(sulfonylmethyl)vinyl]-imidazo[4,5-b]pyridin-derivate und verwandte verbindungen als schädlingsbekämpfungsmittel im pflanzenschutz
AU2018207776B2 (en) 2017-01-10 2021-06-17 Bayer Aktiengesellschaft Heterocyclene derivatives as pest control agents
WO2018130443A1 (de) 2017-01-10 2018-07-19 Bayer Aktiengesellschaft Heterocyclen-derivate als schädlingsbekämpfungsmittel

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL291944A (no) * 1960-05-04
NL131915C (no) * 1966-07-27
DE3508903A1 (de) * 1985-03-13 1986-09-18 Hoechst Ag, 6230 Frankfurt Neue 3-pyridylmethylnaphtylderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3628545A1 (de) * 1985-09-23 1987-04-23 Hoechst Ag Arylmethylazole und deren salze, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung
WO1994008973A1 (en) * 1992-10-21 1994-04-28 Sankyo Company, Limited Azole compound
CA2328973A1 (en) * 1998-04-23 1999-10-28 Akio Ojida Naphthalene derivatives, their production and use
JP4546589B2 (ja) * 1998-04-23 2010-09-15 武田薬品工業株式会社 ナフタレン誘導体
FR2796070B1 (fr) * 1999-07-06 2003-02-21 Lipha Derives de benzodiazepines utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procedes de preparation
PE20010781A1 (es) * 1999-10-22 2001-08-08 Takeda Chemical Industries Ltd Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion
JP4520012B2 (ja) * 1999-10-22 2010-08-04 武田薬品工業株式会社 １−置換−１−（１ｈ−イミダゾール−４−イル）メタノール類

Also Published As

Publication number Publication date
CN1819996B (zh) 2010-10-27
CN1819996A (zh) 2006-08-16
AU2004257257B2 (en) 2011-05-12
AU2004257257A1 (en) 2005-01-27
EP1654236A1 (en) 2006-05-10
WO2005007631A1 (en) 2005-01-27
UA87822C2 (ru) 2009-08-25
JP4832295B2 (ja) 2011-12-07
SG144941A1 (en) 2008-08-28
IL172812A0 (en) 2006-06-11
RU2006103996A (ru) 2006-07-10
JP2007523866A (ja) 2007-08-23
RU2363696C2 (ru) 2009-08-10
IS8223A (is) 2006-01-10
MXPA06000401A (es) 2006-03-17
BRPI0412424A (pt) 2006-09-05
CA2532078A1 (en) 2005-01-27
KR20060052799A (ko) 2006-05-19

Similar Documents

Publication Publication Date Title
NO20060114L (no) Naftylenderivater som cytokrom P450-inhibitorer
NO20054852L (no) GFAT inhibitorer
DK1780197T3 (da) 5-Substituerede 2-phenylamino-benzamider som MEK-inhibitorer
WO2007130075A8 (en) Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
IS2696B (is) Setin 2-amínótetralín fyrir meðhöndlunina á geðdeyfð
ZA200810113B (en) Method for the treatment and prevention of ocular disorders
EA200800006A1 (ru) Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i
NO20081942L (no) Karbamoylbenzotriazolderivater som inhibitorer av lipaser og fosfolipaser
JO2282B1 (en) Oxazole derivatives
DE602007014186D1 (de) Triazin-11-beta-hydroxysteroid-dehydrogenase-artige hemmer
MY146111A (en) Acylaminopyrazoles as fgfr inhibitors
NO20090025L (no) Pyrrolotriazinkinaseinhibitorer
SG148177A1 (en) Novel cis-imidazolines
MY140638A (en) New heterocyclic compounds, which are active as inhibitors of beta-lactamases
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
NO20082159L (no) Triazolopyridinderivater som inhibitorer av lipaser og fosfolipaser
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
DE60107820D1 (de) Neue verwendung von phenylheteroalkylamin-derivaten
EP2639229A3 (en) Thiazole Derivative and use thereof as VAP-1 Inhibitor
SE0301232D0 (sv) Novel use
BR0313407A (pt) Novo uso de derivados de benzotiazol
NO20092035L (no) Tiazolylforbindelser anvendbare som kinaseinhibitorer
WO2008008701A3 (en) Substituted cyclopentane derivatives as therapeutic agents
AU2002215932A1 (en) Nitroderivatives as drugs for diseases having an inflammatory basis
NO20065873L (no) 3-(4-(2-dihydroisoksazol-3-ylpyridin-5-yl)fenyl)-5-triazol-1-ylmetyloksoazolidin-2-on derivater som MAO inhibitorer i behandlingen av bakterielle infeksjoner

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application